Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis

por Verstovsek, Srdan, Yeleswaram, Swamy, Hou, Kevin, Chen, Xuejun, Erickson‐Viitanen, Sue
Publicado 2018

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

por Talpaz, Moshe, Erickson-Viitanen, Susan, Hou, Kevin, Hamburg, Solomon, Baer, Maria R.
Publicado 2018

P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A P...

por Yacoub, A., Borate, U., Rampal, R., Ali, H., Wang, E., Gerds, A., Hobbs, G., Kremyanskaya, M., Winton, E., O’Connell, C., Goel, S., Oh, S., Schiller, G., Assad, A., Erickson-Viitanen, S., Zhou, F., Daver, N.
Publicado 2022

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

por Talpaz, Moshe, Paquette, Ronald, Afrin, Lawrence, Hamburg, Solomon I, Prchal, Josef T, Jamieson, Katarzyna, Terebelo, Howard R, Ortega, Gregory L, Lyons, Roger M, Tiu, Ramon V, Winton, Elliott F, Natrajan, Kavita, Odenike, Olatoyosi, Claxton, David, Peng, Wei, O’Neill, Peter, Erickson-Viitanen, Susan, Leopold, Lance, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Verstovsek, Srdan
Publicado 2013